Return to Clinical Trials Search Results

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Primary Objective: Test whether the experimental combination of ABT-888 (Veliparib) combined with TMZ, compared to the control of placebo combined with TMZ, significantly extends overall survival in newly diagnosed GBM patients with tumor MGMT promoter Hypermethylation. Secondary Objectives: Test whether the experimental treatment significantly extends progression-free survival. Test whether the experimental treatment improves objective tumor response. Test whether the experimental treatment is associated with significantly greater rates of grade 3 or higher adverse events. Correlative Science Objectives: Evaluate the utility of dynamic susceptibility contrast (DSC) and diffusion weighted imaging (DWI) MRI techniques in defining time to progression in the setting of a large multi-institutional clinical trial.



Recruitment Status

Past Studies